Skip to main content

Table 1 Average phase-by-phase attrition rates and phase-by-phase share: 2000–2009 (00), 2010–2013 (10), for the three institutional types under study (pharmaceutical and biotechnological companies, non-industrial institutions)

From: The endless frontier? The recent increase of R&D productivity in pharmaceuticals

Developer Attrition rates
Preclinical Phase I Phase II Phase III Registration
00 10 00 10 00 10 00 10 00 10
Pharmaceutical 86.80 85.16 62.18 58.91 77.74 78.69 64.33 66.40 46.67 32.52
Biotech 90.25 82.17 59.61 54.15 82.20 77.48 78.15 64.14 35.00 22.54
Non-industrial 96.97 97.07 62.37 59.32 90.00 80.19 82.14 81.25 67.65 0
  Share
Preclinical Phase I Phase II Phase III Registration
Developer 00 10 00 10 00 10 00 10 00 10
Pharmaceutical 24.16 24.44 43.99 49.15 47.56 48.34 62.26 62.36 76.69 61.19
Biotech 48.60 43.19 44.54 42.51 42.18 44.18 30.55 32.41 16.36 35.32
Non-industrial 27.24 32.37 11.47 8.33 10.26 7.48 7.19 5.24 6.95 3.48